Aging-related motor function and dopaminergic neuronal loss in C57BL/6 mice

Sachiko Noda 1, Shigeto Sato 1, Takahiro Fukuda 2, Norihiro Tada 3 and Nobutaka Hattori 1*

Abstract

Aging-related dopaminergic neuronal loss and its motor phenotypes are well known. Excessive loss of dopaminergic neurons leads to Parkinson's disease (PD), the most common neurodegenerative disorder characterized by the loss of nigrostriatal dopamine–producing neurons. In mice, however, aging-related dopaminergic neuronal loss and its consequences for motor function are poorly understood. We observed the phenotype of wild-type C57BL/6 mice over an extended period of time. C57BL/6 mice exhibited age-dependent locomotor impairments, including hindlimb defects and the number of dopaminergic neurons decreased in aged mice, contributing to locomotor dysfunction. We observed a reduction in striatal dopamine levels in aged mice using high-performance liquid chromatography (HPLC). Thus, dopamine levels are affected by the loss of dopaminergic neurons. Furthermore, fragmented mitochondria were observed in dopaminergic neurons of aged mice but not in those of young mice. Aging-related dopaminergic neuronal loss and accumulation of damaged mitochondria may underlie the pathophysiology of aging.

Keywords: Dopaminergic neuron, C57BL/6 mouse, Aging, Mitochondria

Main text

Mitochondrial dysfunction has been considered a major contributor to aging and age-related diseases. Mitochondrial dynamics change in advanced age; e.g., mitochondrial biogenesis decreases, while mitochondrial DNA damage and reactive oxygen species (ROS) production both increase [1, 2]. The main source of ROS is the mitochondria. The accumulation of ROS and oxidative damage have been linked to multiple pathologies, including neurodegenerative disorders, diabetes, cancer, and aging. Excessive ROS production is considered an important factor that accelerates the aging process [3, 4]. However, the phenotypes of aged mice have not been fully examined. To elucidate the critical role of aging in dopaminergic neurons, we characterized aging-related pathologies and decreases in motor function in C57BL/6 mice.

We observed C57BL/6 mice over a longer period of time than in other studies. Fall latency during the accelerating rotarod test was reduced in aged mice (Fig. 1a). Latency to fall times were diminished at 120 weeks, compared with young mice (Fig. 1b). C57BL/6 mice were viable at birth and survived (Fig. 1c). And mean body weight was not changed (Fig. 1d). Moreover, in the runway test, young mice exhibited well-coordinated movement and almost no slips of either the forepaw or hindpaw from the beam. By contrast, aged mice could hardly move on the beam and slipped frequently (Fig. 1e, f). In particular, the hindpaws of mice at 120 weeks of age often slipped off the beam (Fig. 1f). To determine how decreasing TH neuron number contributes to aging, we compared the number of TH neurons between
Fig. 1 (See legend on next page.)
aged and younger mice. We sacrificed these mice (70-week-old mice, \( n = 5 \); 120-week-old mice, \( n = 18 \) ) and counted the number of TH neurons in three sections: the ventral tegmental area (VTA), the center area of the substantia nigra pars compacta (SNcc), and the lateral area of the substantia nigra pars compacta (SNcl). Mice at 120 weeks of age had fewer TH neurons than at 70 weeks of age. The reduction in TH cell number was most prominent in the VTA (Fig. 1g, h). No neuronal loss was observed in young mice that did not exhibit motor dysfunction (data not shown). The loss of dopaminergic neurons may contribute to the motor impairment observed in aged mice. In addition, we tested dopamine physiology in 120-week-old aged mice by performing ultrastuctural analysis in dopaminergic neurons of 120-week-old mice. We observed small, round, and fragmented mitochondria in dopaminergic neurons in aged mice (Fig. 1b), but not in young mice (Fig. 1a). Precise quantification revealed that mitochondria area was reduced in dopaminergic neurons in wild-type C57BL/6 mice. Several studies have demonstrated impaired neostriatal functioning due to senescence in rodents. Thus, it has been shown that striatal dopamine content, turnover and uptake [5–7] as well as the number of striatal dopamine receptors are reduced in the senescent male rodent [8, 9]. However, a few studies have attempted to systematically explore the link between these changes in striatal dopamine and motor behavioral deficits in aged mice. Furthermore, there have been no studies concerning dopaminergic neuronal loss in aged mice. In this report, we demonstrated age-dependent dopaminergic neuronal loss (Fig. 1g, h, i) and decrease in dopamine (Fig. 1h). About 35% in the VTA dopaminergic neurons was observed during normal aging. A balance of dopaminergic and cholinergic systems in the striatum has been suggested and imbalance between these two systems can result in movement disorders [10]. Under aging states in the dorsal striatum, an alteration in excitatory and inhibitory transmission mediated by neuromodulators such as dopamine may underlie dysfunctional locomotion. Aging-related neuronal loss has been reported in several areas of the brain. McGeer et al. found that the number of nigral neurons decreases in direct proportion to age, with 48% loss by the age of 60 years [11]. Osterburg et al. [7] reported that dopamine levels decrease within striatal regions in 24–30-month-old mice and C57BL/6 mice clearly do not undergo progressive dopamine loss between 3 and 21 months. Compared with humans, mouse dopaminergic neurons may be affected by aging past 100 weeks. Mitochondrial dysfunction has been considered a major contributor to aging and aging-related diseases. In aged C57BL/6 mice, dopaminergic neurons were filled with small, round mitochondria (Fig. 1j). The mean mitochondrial area was smaller than in younger mice (Fig. 1k).
Fragmented mitochondria were also observed to accumulate in dopaminergic neurons of aged C57BL/6 mice. Previous studies have demonstrated that aging is accompanied by a decrease in mitochondrial dynamics that leads to compromised function and morphological alterations. In both the skeletal muscle and brain of aged individuals, mitochondria have been observed to be enlarged and more rounded [12–14]. On the other hand, Boggi et al. have reported a decrease in mitochondrial size in aged individuals [15]. Changes in mitochondrial volume, shape, and length seem to be a general feature of the human aging process.

The aging-related motor dysfunction and pathology we observed in aged C57BL/6 mice suggest that mitochondrial impairment may underlie aging. We found the accumulation of damaged mitochondria and dopaminergic neuronal loss in aged C57BL/6 mice. Although we require further examination to verify our findings, mitochondria may play a key role in the pathophysiology of aging and may be useful targets for preventing and treating chronic disease, as well as for promoting healthy aging.

Acknowledgments
We thank Dr. Souichiro Kakuta and Dr. Mitsutaka Yoshida (Juntendo University) for technical assistance with electron microscopy.

Authors’ contributions
SS and NH designed the study, analyzed the data, and wrote the paper. SN, TF, NT performed the experiments. All authors read and approved the final manuscript.

Funding
This work was supported by a KAKENHI Grant-in-Aid for Scientific Research from JSPS.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan. 2Division of Neuropathology, Department of Neuropathology, The Jikei University, School of Medicine, Tokyo 105-8461, Japan. 3Atopy Research Center, Juntendo University School of Medicine, Tokyo 113-8421, Japan.

Received: 20 February 2020 Accepted: 10 March 2020
Published online: 23 March 2020

References
1. Christiakov DA, Sobenin IA, Levin W, Orekhov AN, Bobryshev YV. Mitochondrial aging and age-related dysfunction of mitochondria. Biomed Res Int. 2014;2014:238463.
2. Gonzalez-Freire M, de Cabo R, Bernier M, Sollott SJ, Fabbri E, Navas P, et al. Reconsidering the role of mitochondria in aging. J Gerontol A Biol Sci Med Sci. 2015;70:1334–42.
3. Avangigliato A, Bertuzzi G, Pascali M, Candotto V, Carinci F. The theories of aging: reactive oxygen species and what else? J Biol Regul Homeost Agents. 2015;29:15–63.
4. Lopez-Ullch G, Santos-Ocana C, Sanchez-Alcazar JA, Fernandez-Ayala DJ, Asenio-Salcedo C, Rodriguez-Agulera JC, et al. Mitochondrial responsibility in aging process: innocent, suspect or guilty. Biogerontology. 2015;16:599–620.
5. Finch CE. Catecholamine metabolism in the brains of ageing male mice. Brain Res. 1975;2:261–76.
6. Joniec V, Finch CE. Ageing and dopamine uptake by subcellular fractions of the C57BL/6J male mouse brain. Brain Res. 1975;91:197–215.
7. Osterburg HH, Donahue HG, Severson JA, Finch CE. Catecholamine levels and turnover during aging in brain regions of male C57BL/6J mice. Brain Res. 1981;224:337–52.
8. Joseph JA, Berger RE, Engel BT, Roth GS. Age-related changes in the nigrostriatum: a behavioral and biochemical analysis. J Gerontol. 1978;33:643–9.
9. Makman MH, Ahn HS, Thal LJ, Sharpless NS, Dvorbin B, Horowitz SG, et al. Aging and monoamine receptors in brain. Fed Proc. 1979;38:1922–6.
10. Do J, Kim JI, Bakes J, Lee K, Kang BK. Functional roles of neurotransmitters and neuromodulators in the dorsal striatum. Learn Mem. 2012;20:215–21.
11. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol. 1977;34:33–5.
12. Palomer-Avalos V, Grinan-Ferre C, Puigoriol-Ilamola D, Camins A, Sanfeliu C, Canudas AM, et al. Resveratrol protects SAMP8 brain under metabolic stress: focus on mitochondrial function and Wnt pathway. Mol Neurobiol. 2017;54:1661–76.
13. Crane JD, Devries MC, Safdar A, Hamad el MJ, Tamopolsky MA. The effect of aging on human skeletal muscle mitochondrial and intramyocellular lipid ultrastructure. J Gerontol A Biol Sci Med Sci. 2010;65:119–28.
14. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A. 1994;91:10771–8.
15. Boggi P, Marchetti C, Scelsi R. Automatic morphometric analysis of skeletal muscle fibers in the aging man. Anat Rec. 1987;217:30–4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.